FDA Revisits Botanical Drug Pathways with RFI Following Four Approved Products
FDA Addresses Regulatory Bottlenecks for Botanical Drugs
The U.S. Food and Drug Administration (FDA) issued a Request for Information (RFI) on September 3, 2026, to promote the development of botanical drug products. Comments will be accepted for 60 days until November 3, 2026. The RFI targets drugs derived from plants, algae, or macrofungi, or combinations thereof, for the diagnosis, treatment, mitigation, or prevention of disease. Unlike dietary supplements, these products must meet the efficacy and safety standards of a New Drug Application (NDA) or Biologics License Application (BLA). This process is a regulatory policy step to gather input on study design, quality standards, real-world evidence (RWE), and the need for revisions to existing guidance, not a vote by an advisory committee or a decision on individual product approvals.
The Four Approved Products Highlight Regulatory Barriers
Only four botanical drugs have reached the market under FDA standards. Veregen (sinecatechins), a mixture of green tea catechins for the treatment of external genital and perianal warts, was approved on October 31, 2006. Mytesi (crofelemer), which inhibits intestinal epithelial CFTR and calcium-activated chloride channels (CaCC) to manage non-infectious diarrhea in HIV patients on antiretroviral therapy, was approved on December 31, 2012. Filsuvez (larch arabinogalactan), a multi-component mixture involved in wound healing rather than a single molecular target, was approved via NDA on December 18, 2023, for epidermolysis bullosa wounds. NexoBrid (anacaulase-bcdb), a bromelain enzyme mixture derived from pineapple stems for the removal of deep partial- and full-thickness burn eschars, was approved via BLA on December 28, 2022.
Manufacturing Quality is as Critical as Clinical Success
Botanical raw materials vary in chemical composition and biological activity due to factors such as cultivation region, harvest time, climate, and extraction processes. This makes raw material identification, batch consistency, potency testing, and impurity control more complex than for conventional synthetic drugs. The FDA's request for quality standards and clinical design input for complex mixtures reflects the reality that products cannot be easily evaluated using single-molecule targets or traditional pharmacokinetic metrics. While more concrete criteria would allow developers to design early connections between Chemistry, Manufacturing, and Controls (CMC) packages and clinical trials, it does not mean regulatory easing—rather, it emphasizes the need for a reproducible totality of evidence.
Market Expansion Depends on Regulatory Predictability
The global botanical drug market is projected to grow from USD 4.25 billion in 2025 to USD 4.50 billion in 2026 and USD 7.38 billion by 2032, with a compound annual growth rate of 8.2%. Competitive axes for approved products include imiquimod and cryotherapy for genital warts, loperamide and etiology-specific treatments for diarrhea, surgical debridement for burns, and standard wound care plus Krystal Biotech’s Vyjuvek (berepafinogene autotemcel-svdt) gene therapy for epidermolysis bullosa. The FDA also plans a joint workshop with the European Medicines Agency (EMA) on September 25, 2026. If the RFI results align U.S. and European quality and evidence standards, it could reduce development costs and review risks for rare and chronic disease botanical pipelines.
In the short term, industry feedback submitted by November 3, 2026, and the FDA-EMA workshop on September 25, 2026, will be key variables in determining the scope of CMC, clinical design for complex mixtures, and the use of real-world evidence. The fact that only four products—Veregen, Mytesi, Filsuvez, and NexoBrid—have reached the market highlights the low approval productivity relative to the USD 4.50 billion 2026 market size, underscoring the economic value of regulatory clarity. For researchers, validation systems that link raw material fingerprinting, biological potency, and batch consistency to clinical outcomes become increasingly important beyond single-target development. For competitive developers such as Jaguar Health (JAGX), MediWound (MDWD), Vericel (VCEL), and Chiesi, opportunities to shorten development timelines arise, but clinical superiority and manufacturing reproducibility compared to standard treatments like imiquimod, surgical eschar removal, and Vyjuvek will determine company valuations.